NCT07031063View on ClinicalTrials.gov

Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience

PHASE4RecruitingINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2028

Conditions
HIV InfectionMetabolic SyndromeAntiretroviral Treatment
Interventions
DRUG

DTG/3TC

Dual therapy of 2 drugs co-formulated in 1 tablet: Dolutegravir 50 mg/ lamivudine 300 mg, it is the experimental group

DRUG

Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF)

It is a triple-drug antiretroviral drug co-formulated in a single tablet. It contains bictegravir 50 mg, tenofovir alafenamide 25 mg, and emtricitabine 200 mg. It is the standard therapy.

Trial Locations (1)

02990

RECRUITING

Hospital de infectología, Centro Médico Nacional La Raza, Mexico City

All Listed Sponsors
lead

Instituto Mexicano del Seguro Social

OTHER_GOV